STOCK TITAN

Sensus Healthcare Inc - SRTS STOCK NEWS

Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.

Overview of Sensus Healthcare Inc

Sensus Healthcare Inc is a specialized medical device company that has dedicated over a decade to the development of non-invasive treatment solutions using proprietary superficial radiation therapy (SRT) technology. This innovative treatment method is designed for both oncological and non-oncological skin conditions, including various forms of non-melanoma skin cancers and conditions such as keloids, offering a safe and cost-effective alternative to surgical procedures.

Core Technology and Treatment Solutions

The company utilizes a proprietary low energy x-ray radiation system that underpins its SRT technology. This method enables precise targeting of skin lesions while minimizing damage to surrounding tissues. The approach is rooted in extensive research and development, ensuring that each device deployed not only aligns with current clinical standards but also supports a streamlined treatment process. The primary devices in the company’s portfolio are designed to simplify the treatment procedure while ensuring efficacy and patient safety.

Business Model and Revenue Generation

Sensus Healthcare Inc generates revenue primarily through the sale of its specialized SRT treatment devices alongside an associated service program. The revenue model is based on direct transactions with hospitals, oncology centers, and dermatology practices, particularly in the United States. The company’s sales approach integrates product delivery with ongoing support, positioning Sensus as a comprehensive service provider within the medical device industry. This dual-focus on advanced technology and customer service ensures that clients receive not only the equipment but also the necessary operational expertise to maximize treatment outcomes.

Market Position and Industry Significance

Operating within the competitive realm of medical devices, Sensus Healthcare Inc has carved out a niche by focusing on non-invasive superficial radiation therapy. The technology addresses a clear need in the treatment of skin conditions by reducing the potential risks and complications associated with more invasive procedures. With increasing emphasis on patient safety and cost-effectiveness in healthcare, the company’s offerings are well-positioned to provide value within hospital oncology and dermatology departments. Its emphasis on targeted radiation treatment distinguishes its operational approach from other modalities available in the market.

Operational Focus and Customer Base

The company's operational framework is built around delivering effective treatment solutions through both its high-quality devices and a robust support program. The customer base includes major healthcare providers such as hospital oncology departments and specialized dermatology practices. By prioritizing reliability and clinical efficacy, Sensus Healthcare sustains trust within the medical community, ensuring continuous adoption of its technology in outpatient treatment settings.

Clinical Impact and Safety

At the heart of Sensus Healthcare Inc's offerings is a strong commitment to patient safety and treatment efficacy. The non-invasive SRT technique minimizes the need for surgical intervention, thereby reducing recovery times and potential risks associated with more invasive treatments. This clinical approach not only enhances patient outcomes but also supports operational efficiency in healthcare settings by offering a streamlined alternative that aligns with modern treatment protocols.

Competitive Landscape and Differentiation

Sensus Healthcare Inc operates in a dynamic industry where differentiation is critical. The company sets itself apart through its exclusive focus on superficial radiation therapy, a technology with a clear evidential basis in decades of research and clinical application. Although facing competition from traditional and emerging treatment modalities, Sensus leverages its research-backed technology and dedicated service programs to maintain a distinct foothold in the market. Expertise in both technological innovation and customer service elevates its competitive profile as a trusted provider in the non-invasive medical device segment.

Conclusion

In summary, Sensus Healthcare Inc is a specialized medical device entity that combines technological innovation with secure, non-invasive treatment options. Its use of superficial radiation therapy not only underscores advances in medical device innovation but also reflects the company's commitment to enhancing patient care in the treatment of skin conditions. This comprehensive approach, integrating advanced product development with dedicated service programs, positions Sensus Healthcare as a valued participant in a complex and critical segment of healthcare technology.

Rhea-AI Summary

On September 9, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York City. Management will deliver a company overview and conduct one-on-one meetings with investors. A webcast of the presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET on Sensus Healthcare’s website. The company specializes in innovative, non-invasive treatments for various conditions, particularly using its proprietary superficial radiation therapy technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) announced the appointment of Dr. Mohammad K. Khan to its Medical Advisory Board, expanding its expertise in non-invasive treatment for oncological and non-oncological conditions. Dr. Khan, a renowned radiation oncologist at Emory University, specializes in various cancers and aims to enhance Sensus's Superficial Radiation Therapy (SRT) offerings. CEO Joe Sardano expressed optimism about Dr. Khan's contribution to market development for their innovative medical devices. This appointment underscores Sensus's commitment to advancing patient care through expert guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
management
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) has upgraded its SRT-100 Vision™ system with new solid-state High-Frequency Ultrasound technology. This enhancement includes an ergonomic probe for improved handling, allowing visualization of all skin layers, crucial for skin lesion treatment. The system also features electronic medical record capabilities for accurate image capture. CEO Joe Sardano highlighted the increased productivity and resolution of the new system, which is available immediately. Existing customers can upgrade by contacting their sales representatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
none
Rhea-AI Summary

Sensus Healthcare, Inc. (SRTS) reported strong financial results for Q2 2022, achieving revenues of $12.1 million, a 124% increase from Q2 2021. The net income for the quarter was $3.5 million, or $0.21 per diluted share, a significant turnaround from a net loss of $(0.3) million in the previous year. Adjusted EBITDA reached $4.7 million, compared to $(0.1) million in 2021. The company ended the quarter with $33.7 million in cash. Sensus affirms expectations for full-year profitability and highlights strong interest in its new TransDermal Infusion System™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.73%
Tags
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) has sold 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC) in Texas, aimed at non-invasive hair health treatments. The first two systems will be delivered in Q3 2022, followed by the rest in Q4. This system enables painless delivery of U.SK Under Skin's Skin Savers Hair™ serum deep into hair follicles, enhancing patient satisfaction and treatment results. HEC has rapidly expanded from 2 to 9 clinics in 2022, providing hair loss treatments to millions of affected Americans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.66%
Tags
none
-
Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 4, 2022, at 4:30 p.m. ET to discuss its second-quarter 2022 financial results. The management will also provide a business update and details on recent and upcoming milestones. The call can be accessed via phone or live webcast. Following the call, a replay will be available until September 3, 2022. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, featuring proprietary low-energy X-ray technology known as superficial radiation therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.98%
Tags
conferences earnings
Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) has expanded its partnership with Colorado State University (CSU) by supplying a second SRT-100™ system for the study of superficial radiation therapy (SRT) in horses. This initiative takes place at CSU's Johnson Family Equine Hospital, aiming to investigate ophthalmic indications. With SRT showing promising results in earlier studies on other animals, the potential market for veterinary applications is significant, considering there are around 30,000 veterinary practices in the U.S. The CSU team hopes to publish their findings next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
conferences
-
Rhea-AI Summary

On May 18, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022. The company will present on May 25 at 9:30 a.m. Eastern time, with the presentation available live and archived on its website. Additionally, Sensus management, including President Michael Sardano and CFO Javier Rampolla, will hold one-on-one meetings with investors during the conference. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing proprietary low-energy X-ray technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
Rhea-AI Summary

Sensus Healthcare (SRTS) reported first quarter 2022 revenues of $10.3 million, a 237% increase compared to the previous year. Net income surged to $16.1 million, or $0.97 per diluted share, thanks to a $12.8 million gain from asset sales. The company exited the quarter with $32.8 million in cash. Adjusted EBITDA improved to $16.9 million, up from a loss of $0.8 million year-on-year. Sensus affirms expectations for continued growth and profitability in Q2 and the full year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.94%
Tags

FAQ

What is the current stock price of Sensus Healthcare (SRTS)?

The current stock price of Sensus Healthcare (SRTS) is $4.72 as of April 1, 2025.

What is the market cap of Sensus Healthcare (SRTS)?

The market cap of Sensus Healthcare (SRTS) is approximately 77.6M.

What is the primary focus of Sensus Healthcare Inc?

Sensus Healthcare Inc specializes in developing and manufacturing non-invasive superficial radiation therapy devices for treating both oncological and non-oncological skin conditions.

How does Sensus Healthcare generate its revenue?

The company primarily generates revenue through direct sales of its specialized treatment devices and associated service programs to hospital oncology centers and dermatology practices.

What skin conditions are treated with the company's technology?

Their technology is used for treating non-melanoma skin cancers such as basal cell and squamous cell carcinoma, as well as non-cancerous conditions like keloids.

What distinguishes Sensus Healthcare's technology from traditional treatment options?

The company’s proprietary low energy x-ray radiation system offers a non-invasive, cost-effective, and targeted approach, reducing the need for surgical interventions and minimizing damage to surrounding tissues.

Who typically uses Sensus Healthcare's treatment devices?

The primary users are hospitals, oncology departments, and dermatology practices, especially in the U.S., where the non-invasive treatment options provide significant clinical advantages.

How does Sensus Healthcare position itself against competitors?

By leveraging extensive research and a unique focus on superficial radiation therapy, Sensus Healthcare differentiates itself through its commitment to safe, efficient, and non-invasive treatment solutions that are tailored to specific skin conditions.
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

SRTS Stock Data

77.61M
13.57M
17.75%
30.71%
5.13%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON